Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ensysce BiosciencesENSC -5.83%23 3-Year EPS without NRI Growth Rate is 87.60% as of Mar. 2026, which is 1% above its 10-year median of 86.70. GuruFocus rates ENSC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,161 Biotechnology companies, Ensysce Biosciences ranks better than 97.67% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 87.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 71.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Ensysce Biosciences was 87.60% per year. The lowest was 41.70% per year. And the median was 86.70% per year.
Ensysce Biosciences (NAS:ENSC) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ensysce Biosciences 3-Year EPS without NRI Growth Rate Related Terms
ENSC vs GNPX, SXTP, ELAB: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Ensysce Biosciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensysce Biosciences 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ensysce Biosciences's 3-Year EPS without NRI Growth Rate falls into.
Ensysce Biosciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 87.60% mean?
Ensysce Biosciences (ENSC) has a 3-Year EPS without NRI Growth Rate of 87.60% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ensysce Biosciences and its competitors. This is near median its historical median of 86.70. Over the past decade, Ensysce Biosciences' 3-Year EPS without NRI Growth Rate has ranged from 41.70 to 87.60. According to the industry distribution chart, Ensysce Biosciences ranks #27 out of 1161 companies in the Biotechnology industry, placing it in the top 2.3%.
Is Ensysce Biosciences' 3-Year EPS without NRI Growth Rate too high?
Ensysce Biosciences' current 3-Year EPS without NRI Growth Rate of 87.60% is near median its 10-year median of 86.70. Over the past 10 years, this metric has ranged from a low of 41.70 to a high of 87.60. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Ensysce Biosciences' value of 87.60% is 440.7% above this industry median. Based on the distribution chart, Ensysce Biosciences ranks #27 out of 1161 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' 3-Year EPS without NRI Growth Rate compare to GNPX and SXTP?
According to the Biotechnology industry distribution chart, Ensysce Biosciences ranks #27 out of 1161 companies for 3-Year EPS without NRI Growth Rate. This places Ensysce Biosciences in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Ensysce Biosciences' value of 87.60% is 440.7% above this benchmark. Historically, Ensysce Biosciences' own 3-Year EPS without NRI Growth Rate has ranged from 41.70 to 87.60 over the past decade. While the company's 10-year median is 86.70 vs. the industry median of 16.20, Ensysce Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ensysce Biosciences's current 3-Year EPS without NRI Growth Rate of 87.60% is 440.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ensysce Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ensysce Biosciences's current 3-Year EPS without NRI Growth Rate is 87.60%, which is near median its own 10-year median of 86.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSC) has a current 3-Year EPS without NRI Growth Rate of 87.60%. The current 3-Year EPS without NRI Growth Rate is 87.60%, which is near median its 10-year median of 86.70 and 440.7% above the Biotechnology industry median of 16.20. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ensysce Biosciences (ENSC), the current 3-Year EPS without NRI Growth Rate is 87.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score
Get the complete analysis for ENSC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENSC has been successfully added to your 
